Invitae Presents New Data Demonstrating Use of Next-Generation Sequencing for Multi-Gene Panels at the 2015 American College of Medical Genetics Annual Clinical Genetics Meeting

-- Company also expands test catalog; now offers full coverage of CHEK2 gene and four new cancer-related genes --

SALT LAKE CITY & SAN FRANCISCO--()--Invitae Corporation (NYSE:NVTA), a genetic information company, is presenting seven posters at the 2015 American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting, including data demonstrating the use of next-generation sequencing (NGS) technology in genetic testing, a proposed variant classification system based on ACMG guidelines, and genetic testing case studies.

Invitae also announced that it has expanded its test catalog to include four new cancer-related genes, as well as full coverage of CHEK2, a gene associated with increased cancer risk.

“The field of genetics is changing rapidly, and the discovery of the correlation between genes and hereditary disorders is vastly improving patient care. The ability to order full CHEK2—an important option for patients with a personal and family history of breast cancer—is a great example of this,” said Invitae’s Federico Monzon, MD. “Furthermore, Invitae’s offering provides clinicians with an affordable and customizable approach for their patients.”

The new genes include BARD1, MRE11A, RAD50 and CTRC. Invitae has introduced one new multi-gene panel and updated several other panels to incorporate the new genes.

“All Invitae panels with CHEK2 will now offer full coverage of the gene, which is known to play a role in hereditary breast cancer and possibly other cancers, and will enable us to serve more customers and help more patients understand their genetic risk,” said Sean George, president and chief operating officer of Invitae. “This important addition to our test menu is the result of a series of process improvements that we believe will enable us to further expand our test menu throughout the course of the year while maintaining our strategy of lowering the cost of genetic testing. The ongoing expansion of Invitae’s test catalog marks an important step toward the company’s goal of bringing comprehensive, affordable genetic information into mainstream medical practice to improve the quality of healthcare for billions of people.”

Learn more about Invitae’s new and updated panels here.

About Invitae

Invitae’s (NYSE:NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Currently focused on hereditary cancers, Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time and lower price than many single-gene tests today. The company currently provides a single diagnostic service comprising over 200 genes for a variety of genetic disorders associated primarily with cancer, but also covering cardiology, hematology, neurology and pediatrics.

Safe Harbor Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the benefits and attributes of the company’s tests; the belief that process improvements will allow the company to further expand its test menu and maintain its strategy of lowering the cost of genetic testing; and the belief that expansion of its test catalog marks an important step toward the company’s goal of bringing comprehensive genetic information into mainstream medical practice to improve the quality of healthcare. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company's history of losses; the company’s need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the company’s ability to develop and commercialize new tests and expand into new markets; the risk that the company may not obtain or maintain sufficient levels of reimbursement for its tests; risks associated with the company’s ability to use rapidly changing genetic data to interpret test results accurately and consistently; the company’s ability to compete; laws and regulations applicable to the company’s business, including potential regulation by the FDA; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Registration Statement on Form S-1 (including the final prospectus dated February 11, 2015). These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.

NOTE: Invitae and the Invitae logo are trademarks of Invitae Corporation. All other trademarks and service marks are the property of their respective owners.

Contacts

Invitae Corporation
Katherine Stueland, 415-254-1233
pr@invitae.com

Contacts

Invitae Corporation
Katherine Stueland, 415-254-1233
pr@invitae.com